Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials.
Zenaw DebasuHanan Muzeyin KedirTamrat Assefa TadessePublished in: International journal of general medicine (2022)
The combination of rivaroxaban with aspirin is more effective than aspirin alone in the prevention of both MACEs and MALEs in patients with stable CAD and/or PAD. However, the combination treatment is associated with increased of major bleeding. Therefore, the combination of rivaroxaban and aspirin is superior to monotherapy in the management of patients with a high risk of developing MACEs and MALEs.
Keyphrases
- low dose
- cardiovascular events
- coronary artery disease
- antiplatelet therapy
- atrial fibrillation
- venous thromboembolism
- percutaneous coronary intervention
- pulmonary embolism
- peripheral artery disease
- cardiovascular disease
- combination therapy
- type diabetes
- coronary artery bypass grafting
- clinical trial
- study protocol
- replacement therapy
- transcatheter aortic valve replacement
- aortic stenosis
- ejection fraction